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Specificity and ligand affinities of the cocaine aptamer: impact of structural
features and physiological NaCl
Abstract
The cocaine aptamer has been seen as a good candidate for development as a probe for cocaine in many
contexts. Here, we demonstrate that the aptamer binds cocaine, norcocaine, and cocaethylene with similar
affinities and aminoglycosides with similar or higher affinities in a mutually exclusive manner with cocaine.
Analysis of its affinities for a series of cocaine derivatives shows that the aptamer specificity is the consequence
of its interaction with all faces of the cocaine molecule. Circular dichroism spectroscopy and 2-aminopurine
(2AP) fluorescence studies show no evidence of large structural rearrangement of the cocaine aptamer upon
ligand binding, which is contrary to the general view of this aptamer. The aptamer’s affinity for cocaine and
neomycin-B decreases with the inclusion of physiological NaCl. The substitution of 2AP for A in position 6
(2AP6) of the aptamer sequence eliminated the effect of NaCl on its affinities for cocaine and analogues, but
not for neomycin-B, showing a selective effect of 2AP substitution on cocaine binding. The affinity for cocaine
also decreased with increasing concentrations of serum or urine, with the 2AP6 substitution blunting the
effect of urine. Its low affinities for cocaine and metabolites and its ability to bind irrelevant compounds limit
the opportunities for application of this aptamer in its current form as a selective and reliable sensor for
cocaine. However, these studies also show that a small structural adjustment to the aptamer (2AP exchanged
for adenine) can increase its specificity for cocaine in physiological NaCl relative to an off-target ligand.
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ABSTRACT: The cocaine aptamer has been seen as a good
candidate for development as a probe for cocaine in many
contexts. Here, we demonstrate that the aptamer binds
cocaine, norcocaine, and cocaethylene with similar aﬃnities
and aminoglycosides with similar or higher aﬃnities in a
mutually exclusive manner with cocaine. Analysis of its
aﬃnities for a series of cocaine derivatives shows that the
aptamer speciﬁcity is the consequence of its interaction with all
faces of the cocaine molecule. Circular dichroism spectroscopy
and 2-aminopurine (2AP) ﬂuorescence studies show no
evidence of large structural rearrangement of the cocaine
aptamer upon ligand binding, which is contrary to the general
view of this aptamer. The aptamer’s aﬃnity for cocaine and
neomycin-B decreases with the inclusion of physiological NaCl. The substitution of 2AP for A in position 6 (2AP6) of the
aptamer sequence eliminated the eﬀect of NaCl on its aﬃnities for cocaine and analogues, but not for neomycin-B, showing a
selective eﬀect of 2AP substitution on cocaine binding. The aﬃnity for cocaine also decreased with increasing concentrations of
serum or urine, with the 2AP6 substitution blunting the eﬀect of urine. Its low aﬃnities for cocaine and metabolites and its ability
to bind irrelevant compounds limit the opportunities for application of this aptamer in its current form as a selective and reliable
sensor for cocaine. However, these studies also show that a small structural adjustment to the aptamer (2AP exchanged for
adenine) can increase its speciﬁcity for cocaine in physiological NaCl relative to an oﬀ-target ligand.
Probe speciﬁcity plays a vital role in analytical methods. Forthis reason, the reported high speciﬁcities of nucleic acid
aptamers for their analytes and their adaptability to a variety of
analytical platforms have created great interest in aptamers as
selective probes for analytical chemistry. Consequently, the
cocaine aptamer, initially reported to be highly speciﬁc for
cocaine, has been the focus of much investigation.1,2 Recently,
this aptamer’s speciﬁcity has been extended to include
norcocaine and the oﬀ-target ligand quinine.3−6 Since the
cocaine-binding activity of the original MNS-4.1 aptamer was
reported,1 many functional variants of this aptamer have been
reported. Here we report on the speciﬁcity, ligand binding, and
structure of three sequence variants of the cocaine aptamer2,7
and some of their 2-aminopurine (2AP)-substituted variants.
Our results demonstrate that the aptamer discriminates the
cocaine structure at all faces of the molecule. It also binds two
important metabolites, norcocaine and cocaethylene, and
several aminoglycosides with aﬃnities similar to or higher
than that for cocaine. Contrary to the predominant view of the
binding mechanism of this aptamer, our results clearly show
that the cocaine aptamer undergoes very minor structural
changes on binding its ligand and that small variations in
sequence can alter its ligand aﬃnities. The results suggest that
the most robust analytical applications of the cocaine aptamer
are limited to analyte mixtures of low complexity with high
concentrations of cocaine. The most eﬀective sensor platforms
are likely to be those that rely on properties other than large
structural changes in the aptamer upon binding analyte.
■ MATERIALS AND METHODS
Cocaine Aptamers. Cocaine aptamers (Supporting In-
formation Table S1) were from Integrated DNA Technologies
(Coralville, IA, USA) or from Iowa State University DNA
Facility (Ames, IA, USA) as standard desalted preparations.
2AP-modiﬁed aptamers were characterized by their λex = 303 or
307 nm and λem = 370 or 371 nm. The aptamers are named
according to their nt length and substituents and ending with
#A to signify that the sequence has been identiﬁed as one of an
aptamer series. Therefore, 38COC1−2AP6A is a 38 nt long
cocaine aptamer with 2-aminopurine in position 6 and #1 in the
series.
Biological Samples. Institutional Review Board (IRB)
approved viral-tested human pooled urine was obtained from
Bioreclamation Inc. (Westbury, NY, USA). The donors were
verbally screened to be free of recreational drugs. Charcoal-
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stripped fetal bovine serum (FBS) was purchased from Sigma
(St Louis, MO, USA).
Analytes. Cocaine (COC), norcocaine (NOR), coca-
ethylene (COE), benzoylecgonine (BZE), ecgonine methyl
ester (EME), ecgonine ethyl ester (EEE), ecgonine (ECG), and
anhydroecgonine methyl ester (AME) samples, dissolved in
acetonitrile or methanol, were from Cerelliant (Round Rock,
TX, USA). The analytes were separated from acetonitrile or
methanol by initial dilution in deionized water followed by
dehydration under vacuum during centrifugation (1400 rpm in
an Eppendorf Vacufuge) for two cycles, each for 45 min at 60
°C. Protocols for synthesizing other cocaine analogues (6,7-
dehydrococaine, 6,7-dehydrococaine-tert-N-BOC, 6,7-dehydro-
biotinylcocaine, 6,7-dehydronorcocaine, and 6,7-bis(4-
methylthiobenzoyloxy)cocaine) are in the Supporting Informa-
tion (Figures S1 and S2). Neomycin-B, paromomycin, and
ribostamycin were purchased from Sigma-Aldrich.
Isothermal Titration Calorimetry. Isothermal titration
calorimetry (ITC) experiments were performed using a VP-
ITC isothermal titration calorimeter (Microcal, Inc., North-
hampton, MA,USA) or NanoITC (TA Instruments, New
Castle, DE, USA). The cocaine in the syringe and the cocaine
aptamer in the cell were in buﬀer A (20 mM Tris, pH 7.4, 140
mM NaCl, 5 mM KCl) or buﬀer B (buﬀer A lacking NaCl)
with the inclusion of urine or serum where indicated. All buﬀer
pHs were measured at room temperature (23−24 °C) after
their complete formulation.
Fluorescence Measurements. Fluorescent spectra were
obtained using a Cary Eclipse ﬂuorescence spectrophotometer
(Agilent Technologies, Santa Clara, CA, USA) with samples in
a quartz cuvette at λex = 303 or 307 nm and an emission scan of
340−585 or 320−450 nm, with a 5 or 10 nm slit. The PMT
voltage was set to high. The maximum emission peak at 371 nm
for each spectrum was selected for data analysis. OriginPro 8.6
was used to determine dissociation constants from the data
obtained by steady state ﬂuorescence quenching.
Circular Dichroism. Circular dichroism (CD) measure-
ments were performed in a 0.1 cm path-length quartz cell with
a Jasco J-710 spectropolarimeter at 25 °C with aptamers in 5
mM KCl, 20 mM Tris, pH 7.4. Data were collected from 200 to
300 nm with a scanning speed of 50 nm/min, resolution of 0.2
nm, bandwidth of 1.0 nm, sensitivity of 20 mdeg, and time
response of 8 s. CD spectra (an average of results from two
independently prepared aptamer solutions) are presented as the
mean residue ellipticity, [θ] (deg·cm2/dmol) vs wavelength
(nm). CD data were analyzed by the program JFIT.
Gel Electrophoresis. Samples of cocaine aptamer
incubated with or without exonuclease I (New England
BioLabs, Ipswich, MA, USA) were resolved by nondenaturing
polyacrylamide gel electrophoresis (PAGE), run for 3 h at
constant 150 V in 90 mM Tris, 90 mM boric acid, and 2 mM
EDTA, pH 8.0. Acrylamide:bis(acrylamide) (37.5:1) was used
to prepare the 15% acrylamide gel.
Statistical Analysis. Where indicated, statistical analyses
were performed by an independent-samples two-tailed t test.
Figure 1. Minimal structural transition in the cocaine aptamer with ligand binding. (A) Proposed secondary structure of cocaine aptamer6 with the
positions of 2AP substitution identiﬁed by orange circles and cocaine by the green circle. S1, S2, and S3 are the stems. (B) The cocaine aptamer
(Apt) or oligo40 (Oligo) was incubated for 0 or 2 min with 0.08 U/mL exo I and then the reaction stopped by bringing the solution to 1 mM
EDTA. (C) A series of cocaine aptamers at 4 μM, each modiﬁed at a diﬀerent position, were incubated with 200 μM cocaine. The ﬂuorescence (λex =
303 nm; λem = 371) was measured in the presence and absence of cocaine in buﬀer A. The diﬀerence (without cocaine subtracted from with cocaine)
is plotted. (D) Circular dichroism spectra of 38COC1A and 30COC2A in 20 mM Tris, 5 mM KCl, pH 7.4, each in the presence and absence of
cocaine.
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■ RESULTS AND DISCUSSION
Structural Changes in the Cocaine Aptamer Accom-
panying Cocaine Binding. When bound to cocaine, the
cocaine aptamer is believed to have a folded structure that
consists of three stems (S1, S2, and S3) intersecting at a three-
way junction (Figure 1A). It has frequently been represented as
shifting from a largely unfolded structure (with only S2 intact)
to one that is folded with bound cocaine.1 This original model
of a structure-switching aptamer, although pervasive in the
literature, was shown by EPR and NMR analysis to be incorrect
for S3, which was demonstrated to remain intact in the absence
of cocaine for all versions of the cocaine aptamer tested.7,8
However, in a version of the aptamer with a 3 bp S1 stem, this
stem was reported as unstructured in the absence of cocaine.8
The shorter stem also decreases the aptamer aﬃnity for cocaine
to 28−45 μM (Kd), which is 4−5-fold lower than for a version
of the aptamer with a longer stem.7 An examination of the
literature from the past 3 years shows that the vast majority of
sensors developed to incorporate the intact cocaine aptamer
included the longer S1 stem,5,9−22 with occasional comparisons
of the short and long S1 aptamers.5,16 Sensors have also been
infrequently reported based on intact short stem cocaine
aptamers.23,24
To understand the extent of structural unfolding that occurs
with the cocaine aptamer, we ﬁrst examined the most
frequently employed aptamer with a longer S1 (38COC1A)
that has been proposed to form a helix in the absence of
cocaine.7,8 If S1 in 38COC1A exists as a helical structure in the
absence of cocaine, it should resist degradation by 3′
exonuclease I (Exo I), which is speciﬁc for single-stranded
DNA. The control oligonucleotide for Exo I activity was a 40 nt
oligomer (Oligo40) for which no signiﬁcant structure was
predicted by MFold.25 Whereas Oligo40 was completely
degraded after 2 min with 0.08 U/μL Exo I, 38COC1A was
unaﬀected (Figure 1B). Therefore, in the absence of cocaine,
38COC1A appears to be completely folded including the S1
stem.
To determine the extent to which the cocaine aptamer
structure shifts with cocaine binding, we examined a series of
cocaine aptamer derivatives each with a single adenine (A)
substituted by 2AP at positions 4, 6, 8, 9, 23, 36, and 38
(sequences in Table S1). Stacking of 2AP with other bases
quenches the ﬂuorescence of this purine analogue.26 Small
changes in ﬂuorescence were observed to accompany cocaine
binding to aptamer variants containing 2AP at various positions
throughout the molecule with all but one change being a lower
ﬂuorescence in the presence of cocaine compared with the apo-
aptamer (Figure 1C). The small change in ﬂuorescence yield
for the 3′ base (55−59% of that for the free 2AP base) suggests
a small structural adjustment. This result is consistent with the
small change in ﬂuorescence quenching of a 3′ terminal
ﬂuorophore when the 5′ end was labeled with a matched
quencher.27
We also examined the eﬀects of cocaine on the secondary
structures of 30COC2A (S1 = 3 bp) and 38COC1A (S1 = 6
bp) by CD spectroscopy (Figure 1D). The results clearly
support the conclusion that the aptamer does not undergo a
large change in secondary structure on binding cocaine even
when the S1 stem is short.
Aﬃnity of the Cocaine Aptamer and 2AP Derivatives
for Cocaine. Although 2AP is considered a silent replacement
of A because it also base-pairs with thymine,28 it diﬀers from A
in some of its base-pairing options and its presence introduces
small perturbations in the DNA helix structure.29 Small local
perturbations due to the replacement of A by 2AP could be
ampliﬁed to larger changes in tertiary structure that might alter
the aptamer’s interactions with ligands. To investigate if the
incorporation of 2AP into the cocaine aptamer changed its
structure, we determined the aﬃnities for cocaine of the
aptamer and each of its 2AP derivatives. A large range of values
(1 nM to 1 mM) has been reported for the aﬃnity of the
cocaine aptamer for cocaine.2,4,8,27,30−36 This variation may be
due to a combination of diﬀerences in aptamer sequence and
assay conditions used in these studies. Consequently, we
determined the aﬃnities for cocaine of several versions of the
cocaine aptamer by ITC under the same conditions (Table 1
and Figure S3). All tested aptamer variants displayed Kds for
cocaine of 10−20 μM.
As a control to establish that the aptamer DNA structure is
critical for cocaine binding, we tested the ability of 38COC1A-
RNA to bind cocaine. This oligonucleotide has the same base
sequence as 38COC1A, but the H in the 2′ positions are
replaced by OH and the methyl group on the thymidine is
absent in the uracil substitution. These small structural changes
resulted in an oligonucleotide that does not bind cocaine
(Figure S4), thereby demonstrating the importance of structure
over sequence in the cocaine aptamer.
For some 2AP substitutions the changes in ﬂuorescence due
to cocaine binding were suﬃciently large to be used as
monitors of cocaine binding (Figure 1C). With 2AP
Table 1. Speciﬁcity of the Cocaine Aptamer
Kd + std dev (μM)
cocaine analogue 38COC1A 36COC3A 38COC1−2AP23A 38COC1−2AP6A
cocaine 15 ± 6.2 20 ± 3.6 15 ± 2.8 28 ± 13a 9.2 ± 2.1
cocaethylene 9.8 ± 5.6 15 ± 2.4 11 ± 2.6 ND 6.5 ± 0.74
norcocaine 13 ± 3.0 12 ± 4.6 9.3 ± 0.75 ND 5.2 ± 0.87
ecgonine NB NB NB ND 73, NBb
6,7-dehydronorcocaine 56 ± 23 80 ± 17 ND ND ND
6,7-dihydroxycocaine 95, NBb ND ND ND ND
aThe aﬃnities of two cocaine aptamers and the 38COC1A aptamer with 2AP substituted for A at position 6 (38COC1−2AP6A) or 23 (38COC1−
2AP23A) were determined by ITC for cocaine and cocaine analogues with the exception of one value, which was determined by 2AP steady state
ﬂuorescence quenching. All values are the average of at least two independent estimates with the values for cocaine being the averages of three to ﬁve
independent estimates. bTwo independent estimates for which one gave no binding and the other low aﬃnity binding. Standard deviations are for
independent estimates. The following analogues were also tested with two independent trials and found not to be bound by the aptamer:
anhydroecgonine, benzoylecgonine, 6,7-bis(4-methylthiobenzoyloxy)cocaine, cocaine-tert-N-biotin, 6,7-dehydrococaine-tert-N-Boc, ecgonine ethyl
ester, and ecgonine methyl ester. NB, no binding; ND, not determined.
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ﬂuorescence as the readout (Figure 2A), we determined the Kd
of 38COC1−2AP23A to be not signiﬁcantly diﬀerent from the
Kd obtained by ITC (Table 1). Nucleic acids with 2AP
substituted for A in a speciﬁc position have been used in many
studies to interrogate changes in nucleic acid structure with the
implicit assumption that 2AP substitutions do not alter the
nucleic acid structure.28,37−39 We tested this assumption for the
cocaine aptamer and found that the aﬃnities for cocaine of
most 2AP-substituted aptamers were comparable with that of
the unsubstituted aptamer (Figure 2B). However, 2AP
substitution in two positions (4 and 8) decreased the aﬃnity
compared with the unsubstituted aptamer (P = 0.0006 and 0.01
for positions 4 and 8, respectively). Excluding the results from
these two substituted aptamers, which are likely altered in
structure by 2AP substitution, our results are consistent with
the conclusion that all stems of the apo-aptamer (ligand-free)
are folded in the absence of cocaine and that very small
structural changes occur throughout the molecule with cocaine
binding (Figure 1C,D). These results are consistent with the
reports of others.5,7,8
To test for independent eﬀects of cocaine on 2AP
ﬂuorescence, the structures of the 38COC1−2AP derivatives
were distorted by annealing them with a complementary 20 nt
oligonucleotide (cDNA(1−20)) that covers the presumptive
cocaine-binding pocket. These hybrid molecules showed no
change in 2AP ﬂuorescence upon the addition of cocaine,
cocaine metabolites, or neomycin-B (Figure S5). Analyses by
ITC showed that these distorted 38COC1A hybrids were not
functional aptamers (Figure S6).
These results suggest that, rather than being explained by a
large change in secondary structure as originally proposed for
the cocaine aptamer, the ligand-driven changes in spectral
characteristics,27 electrochemical signals,40,41 and bending of
aptamer-decorated microcantilevers42 are likely to be reporting
on a change in its tertiary structure as was recently
demonstrated by small-angle X-ray scattering analysis of the
eﬀect of cocaine on the aptamer’s shape.5
Speciﬁcity of the Cocaine Aptamer for Cocaine and
Related Compounds. Because speciﬁcity is an important
feature that identiﬁes aptamers as desirable probes for detecting
analytes, we examined the ability of the 38COC1A to bind a
range of cocaine analogues, including the major cocaine
metabolites, for which modiﬁcations are located variously
around the core molecule. Our results show that the aptamer
binds cocaine, norcocaine, cocaethylene, and 6,7-dehydronor-
cocaine with aﬃnities in the range of 10−56 μM and to 6,7-
dihydroxycocaine with lower aﬃnity, but does not bind any
other analogue tested (Table 1). Similar results were found by
ITC and steady state 2AP ﬂuorescence quenching (Figure 3A)
and also for the 36COC3A aptamer.
Evaluation of the molecular features of analogues that bound
and did not bind the cocaine aptamer suggests that this aptamer
fully surrounds cocaine in the aptamer−ligand complex (Figure
3B and Table 1). The results show that addition of molecular
bulk (even a methyl group) to the N8 position of cocaine
decreases the aptamer aﬃnity (cf. norcocaine and cocaine;
Table 1). The C2-linked methyl or ethyl esters and the
phenylester at C3 promote aptamer binding (cf. cocaine and
anhydroecgonine methyl ester). Cocaine derivatives containing
either a double bond or hydroxyl groups at positions C6 and
C7 bound poorly, which showed that the C6−C7 face of the
cocaine molecule also interacts with the aptamer. These results
show that all faces of cocaine bind to the aptamer and suggest
that speciﬁcity for cocaine may result from the ligand being
buried in the DNA as has been observed for other aptamer−
ligand interactions.43
Originally reported to bind cocaine and neither benzoylec-
gonine nor ecgonine methyl ester,2 the aptamer was later
shown to also bind norcocaine.4,6 We show here that it also
binds cocaethylene with an aﬃnity similar to that for cocaine
and more tightly with norcocaine. Broadening the speciﬁcity of
the cocaine aptamer to cocaethylene, a cocaine metabolite
associated with ethanol consumption44,45 is noteworthy
because drugs are often consumed in combination with
alcohols.
Heterologous Ligands Bound by the Cocaine Ap-
tamer. To further explore the ligand selectivity of the cocaine
aptamer, we examined its ability to bind aminoglycosides, a
class of antibiotics that recognize many RNA structures.46 We
report for the ﬁrst time that the cocaine aptamer binds the
three tested aminoglycosides with aﬃnities in the same
concentration range as those for cocaine and metabolites
(Table 2). These results are consistent with our observations
that the aptamer exists in a primarily folded state when not
bound to cocaine such that it can capture aminoglycosides, but
they are unexpected because aminoglycosides generally bind to
RNA and not DNA. DNA aptamers have recently been isolated
for aminoglycosides, but their structures are unknown.47,48 A-
DNA is reported to bind aminoglycosides,49 but our CD
spectra clearly identify the cocaine aptamer structure as B-DNA
(Figure 1D).
Eﬀect of NaCl on Cocaine Aptamer Aﬃnities. The
aﬃnities and speciﬁcities of aptamer−analyte interactions can
be inﬂuenced by salt composition, which can vary between
biological samples.50,51 The eﬀect of physiological (140 mM)
NaCl was to decrease the aﬃnities of 38COC1A for cocaine
and neomycin-B by 4-fold and 2-fold, respectively (Figure 4A).
This consistency between ligands suggests a global eﬀect of
NaCl on aptamer structure rather than an eﬀect on speciﬁc
ligand−aptamer contacts. Several secondary structures were
predicted by MFold25 of 38COC1A in the presence of 5 and
140 mM NaCl (Figure 4D), but not those originally proposed
for this aptamer (Figure 1A). These folding predictions, in
combination with the evidence (Figures 1B−D) that binding
cocaine results in little change in secondary structure of the
aptamer, suggest that the structural stability of 38COC1A
derives mainly from tertiary structural interactions that may
Figure 2. 2AP scan for structural changes in the cocaine aptamer with
cocaine binding. (A) Percent ﬂuorescence quenching (at 371 nm) of
38COC1−2AP23A with increasing cocaine in buﬀer A. The measured
Kd was 30 μM. (B) Kds of aptamers with site-speciﬁc 2AP
modiﬁcations for cocaine in buﬀer A determined by ITC. Data for
the unmodiﬁed cocaine aptamer are plotted in the 0 2AP position.
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impose a consistent base-pairing pattern on the aptamer. The
homogeneity of folding is evidenced by (1) N values of ∼1.0
from ITC measurements of binding to cocaine, norcocaine, and
cocaethylene, (2) a single form on nondenaturing electro-
phoresis (Figure 1C), and (3) the CD spectra (Figure 1D) of
this aptamer. The eﬀect of NaCl on the aptamer aﬃnity might
be explained by the ability of monovalent cations to destabilize
folded DNA structures.52−55 If so, a related aptamer with a
more stable secondary structure might not be aﬀected by NaCl
concentration. We tested this hypothesis with 36COC3A,
which is predicted by MFold25 to adopt one of two structures
in the presence of both 5 and 140 mM NaCl, each with three-
way junctions (Figure 4E). As for 38COC1A, aﬃnities of
36COC3A for cocaine, cocaethylene, and norcocaine were
decreased by the inclusion of 140 mM NaCl (Figure 4B). This
suggests that, although the eﬀect of NaCl on aptamer structure
Figure 3. Speciﬁcity of the cocaine aptamer for cocaine analogues and metabolites. (A) 38COC1−2AP23A aﬃnity for cocaine and its metabolites
showing interassay variabilities for ﬂuorescence and ITC measurements. (B) Functional groups in cocaine that promote 38COC1A aptamer
recognition are circled. Moieties that decrease aﬃnity for cocaine are surrounded by rectangles with dashed borders.
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is likely to be global, it is not driven by the strength of the S1
stem.
In contrast with 38COC1A, there was no eﬀect of NaCl on
cocaine aﬃnity of the variant aptamer, 38COC1−2AP6A with
2AP substituted for A in position 6 (Figure 4C). However, the
aﬃnity of 38COC1−2AP6A for neomycin-B was decreased
more by NaCl than seen with 38COC1A. The 2AP6
substitution also changed the speciﬁcity of 38COC1A from
norcocaine = cocaethylene > cocaine to cocaethylene >
norcocaine > cocaine (Table 1 and Figure 4C).
The selective eﬀect of 2AP on the sensitivity to NaCl of the
aptamer for cocaine binding compared with neomycin-B might
be because neomycin-B binds in a distinct region of the
aptamer from cocaine allowing a local eﬀect on the cocaine-
binding pocket to selectively alter the aptamer response to
NaCl for cocaine. To establish if neomycin-B and cocaine
bound the same locations on the aptamer, we determined the
aﬃnity by ITC when the two compounds were titrated
separately into the aptamer or as a stoichiometric mixture.
Separately and in combination, the ligands bound with
estimated N values of ∼1 (Table 3 and Figure S7). The
measured Kd for the combination of ligands was the average of
the Kds calculated from titrations with each ligand separately.
These results demonstrate that neomycin-B and cocaine bind
Table 2. Aﬃnities for Aminoglycosides of the Cocaine Aptamera
aminoglycoside, aptamer analysis method Kd ± std dev (μM)
neomycin-B, 38COC1A ITC 4.5 ± 0.6
neomycin-B, 38COC1−2AP23A ﬂuorescence quenching 15 ± 4.0
paramomycin, 38COC1A ITC 10 ± 3.4
ribostamycin, 38COC1A ITC 75 ± 4.4
aThe cocaine aptamers 38COC1A and 38COC1−2AP23A, for which the sequences can be found in Table S1, were tested for aﬃnity for each of
three aminoglycosides by ITC or 2AP ﬂuorescence quenching.
Figure 4. Eﬀect of NaCl on the binding aﬃnities of cocaine aptamers. Aﬃnities of 38COC1A (A), 36COC3A (B), and 38COC1−2AP6A (C) for
cocaine, cocaethylene, norcocaine, and neomycin-B in the presence of 5 mM KCl (red and orange) or 5 mM KCl, 140 mM NaCl (green and
purple). The sequences of the two aptamers are compared in (D) with the diﬀerences identiﬁed in red shading and the position of the 2AP in
38COC1−2AP6A identiﬁed with green shading, Secondary structure predictions are given for 38COC1A (E) and 36COC3A (F) at 24 °C in 5 mM
or 140 mM NaCl. No folding was predicted for either aptamer in the absence of NaCl. Although K+ and Na+ may interact diﬀerently with DNA, the
MFold web server provides no option for folding in the presence of KCl. Therefore, 5 mM NaCl was used as a surrogate for 5 mM KCl.
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to the same site on the molecule, thereby ruling out two
binding sites as an explanation for the diﬀerential eﬀect of the
2AP substitution on the NaCl sensitivity of aﬃnities for cocaine
and neomycin-B.
Eﬀect of Biological Fluids on Cocaine Aptamer
Aﬃnities. Cocaine is excreted in urine as cocaine (1−9%),
benzoylcocaine (35−45%), ecgonine methyl ester (32−49%),
and ecgonine.56,57 Of the metabolites that the aptamer binds,
only norcocaine (∼60 nM) is present in urine samples.58
Individuals who have consumed alcohol also excrete coca-
ethylene.44 Although human plasma and saliva can also contain
cocaine at average concentrations of 3 and 31 μM,
respectively,59 urine is the biological matrix of choice because
it can be obtained noninvasively and contains detectable
concentrations of cocaine and its metabolites.60 In the presence
of 55% serum, the aﬃnity of the 38COC1A aptamer for
cocaine was very low and diﬃcult to measure, whereas
38COC1−2AP6A and 38COC1−2AP23A retained their
abilities to bind cocaine. Therefore, studies of the eﬀects of
urine and serum on the binding aﬃnity for cocaine were limited
to 38COC1A modiﬁed with 2AP substitution for A at positions
6 and 23, respectively (Figure 5). The cocaine aﬃnity of
38COC1−2AP6A was much less aﬀected by urine than by
serum. In contrast to 38COC1−2AP6A, 38COC1−2AP23A
demonstrated a much larger decrease in aﬃnity for cocaine with
increasing urine concentration. This observation that the
placement in the aptamer sequence of a modiﬁed base can
alter its performance in particular analyte matrices is consistent
with the notion that the 2AP substitution can aﬀect tertiary
structure.
The aptamer aﬃnities shown in Figure 5 were determined
with the NaCl concentration adjusted to the same value at all
concentrations of biological ﬂuids tested. Thus, these
observations suggest that, in addition to NaCl, other
components of these biological ﬂuids also decrease the
aptamer’s aﬃnity for its ligands. In a practical sense, these
eﬀects on Kd dampen the response of the aptamer to cocaine in
these ﬂuids and result in an underestimate of the cocaine
concentration unless standard samples are dissolved in the
equivalent ﬂuid for analysis.
One concern for the accuracy of aﬃnity values determined in
the presence of biological ﬂuids is the possible inﬂuence of
cocaine degradation during the analysis period. The reported
half-lives for cocaine in plasma and urine are approximately 2
and 9 h, respectively.61,62 Although instability of cocaine in
these biological ﬂuids may have some impact on the measured
dissociation constants, the observed decreases in aﬃnity are
inconsistent with a conclusion that ligand decay is the major
factor inﬂuencing the measured aﬃnity. First, at the end of a 2
h ITC run and with the reported decay rates, cocaine would be
at a minimum 50% (assuming the same decay rate in serum as
for plasma) or 85% (in urine) of the initial concentration,
which would result in a maximum 2-fold increase in apparent
Kd. But, the observed decreases in Kd are up to 5-fold of the
control. Second, were the degradation of cocaine in urine
responsible for the increased aﬃnity, both 2AP-modiﬁed
aptamers would be similarly aﬀected in their aﬃnity with
incremental changes in urine concentration. But, with the same
batch of urine, the pattern and extent of change in Kd is
diﬀerent for 38COC1−2AP6A and 38COC1−2AP23A (Figure
5).
■ CONCLUSIONS
Having evaluated the aﬃnity of the cocaine aptamer for a broad
range of cocaine metabolites and synthetic derivatives, we
conclude that the aptamer interacts with all faces of the cocaine
molecule. Despite this evidence that the cocaine is buried in the
binding pocket, there are several troublesome oﬀ-target ligands
that bind with similar or higher aﬃnities (cocaethylene,
norcocaine, aminoglycosides, and quinine),3−6 which compli-
cate the application of this aptamer in a cocaine sensor.
Although it is common for aptamers to respond to divalent
cations such as Mg2+, we have found that the cocaine aptamer is
sensitive to NaCl. The results suggest that the eﬀect is
structural and the substitution of 2AP for A in position 6 of
38OC1A abrogates the eﬀect of NaCl on the aﬃnity for cocaine
and its analogues but not for neomycin-B. Thus, NaCl lowers
the aptamer aﬃnity for cocaine but raises its speciﬁcity for
cocaine over neomycin-B.
These results suggest that selective 2AP substitution of the
cocaine aptamer might be a route to increasing its speciﬁcity
and decreasing its responsiveness to environmental factors and
biological matrix components. Additional structural stability
required for good performance might be achieved by choosing
the appropriate platform for application. For example, the
observation that molecular crowding stabilizes nucleic acid
structures63,64 suggests optimal performance on platforms in
which the aptamer is densely arrayed. At least three
immobilized aptamers (cocaine,42 thrombin, and Lcn265)
Table 3. Interaction of the Cocaine Aptamer with Cocaine
and Neomycin-Ba
ligand Kd (μM) N
cocaine 15 ± 6.2 (5) 0.7 ± 0.4 (4)
neomycin-B 4.5 ± 0.6 (2) 1.0 ± 0.1 (2)
av of cocaine and neomycin-B 11 0.9
cocaine plus neomycin B 11 ± 0.9 (2) 1.1 ± 0.01 (2)
aThe aﬃnities and N values of 38COC1A for cocaine and neomycin-B
and an equimolar mixture of cocaine and neomycin-B are shown in
addition to the average values for Kd and N for cocaine and neomycin-
B. Shown also are the standard deviations and the number of
independent estimates (in parentheses) for each value. The data for Kd
for cocaine and neomycin-B are also shown in Tables 1 and 2,
respectively. Representative titrations are shown in Figure S6.
Figure 5. Eﬀects of biological ﬂuids on the binding aﬃnities of cocaine
aptamers. Aptamers modiﬁed at positions 6 (38COC1−2AP6A) and
23 (38COC1−2AP23A) with 2-aminopurine were tested by ITC for
their binding aﬃnities for cocaine in the presence of a range of
concentrations of urine (●, ο) or fetal bovine serum (Δ). Two batches
(B1, B2) of urine were tested.
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demonstrated higher aﬃnities for their ligands when they were
immobilized compared with when they were in solution.
Its low aﬃnity for cocaine, the eﬀect of biological ﬂuids on
cocaine aﬃnity, and the presence of several oﬀ-target ligands
with similar aﬃnities limit the application of this aptamer to the
identiﬁcation of cocaine and some of its analogues when they
are present at high concentrations, in samples of known
composition, in conjunction with tests for oﬀ-target ligands and
standard samples in the same matrix as the analyte. However,
the observation that aptamer aﬃnity and speciﬁcity can be
altered by selective substitution of 2AP for A in the DNA
sequence suggests future opportunities for engineering this
aptamer for higher aﬃnity and speciﬁcity and less responsive-
ness to matrix components and salt compositions.
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